How can proteomics elucidate the complexity of multiple sclerosis?

Proteomics - Clinical Applications

Volumn 9, Issue 9-10, 2015, Pages 844-847

  Farias, Alessandro S ^a   Santos, Leonilda M B ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Experimental autoimmune encephalomyelitis; Inflammation; Multiple sclerosis; Neurodegeneration; Proteomics

Indexed keywords

HLA DR2 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AUTOIMMUNITY; ENVIRONMENTAL FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; ANIMAL; DEGENERATIVE DISEASE; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PROTEOMICS;

EID: 84942990169     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400171     Document Type: Article

References (41)

1. Ramagopalan, S. V., Dobson, R., Meier, U. C., Giovannoni, G., Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010, 9, 727-739.
2. vonGlehn, F., Brandao, C. O., Farias, A. S., Santos, L. M. B., Young perspectives for old diseases - Multiple Sclerosis: An Overview, Bentham Science Publishers 2014, 1, 223-250.
3. Haines, J. L., Ter-Minassian, M., Bazyk, A., Gusella, J. F. et al., A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet. 1996, 13, 469-471.
4. International Multiple Sclerosis Genetics Consortium, Network-based multiple sclerosis pathway analysis with GWAS data from 15000 cases and 30000 controls. Am. J. Hum. Genet. 2013, 92, 854-865.
5. International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham, A. H., Patsopoulos, N. A., Xifara, D. K. et al., Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 2013, 45, 1353-1360.
6. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer, S., Hellenthal, G. et al., Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476, 214-219.
7. Sawcer, S., Franklin, R. J. M., Ban, M., Multiple sclerosis genetics. Lancet Neurol. 2014, 13, 700-709.
8. Baranzini, S. E., Nickles, D., Genetics of multiple sclerosis: swimming in an ocean of data. Curr. Opin. Neurol. 2012, 25, 239-245.
9. Westerlind, H., Ramanujam, R., Uvehag, D., Kuja-Halkola, R. et al., Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain 2014, 137, 770-778.
10. Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J. P. A., Tzoulaki, I., Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015, 14, 263-273.
11. Baranzini, S. E., Mudge, J., vanVelkinburgh, J. C., Khankhanian, P. et al., Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010, 464, 1351-1356.
12. Sajedi, S. A., Abdollahi, F., Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries. BMC Neurol. 2012, 12(100), 1-18.
13. Hafler, D. A., Slavik, J. M., Anderson, D. E., O'Connor, K. C. et al., Multiple sclerosis. Immunol. Rev. 2005, 204, 208-231.
14. Hauser, S. L., Oksenberg, J. R., The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52, 61-76.
15. Steinman, L., Immunology of relapse and remission in multiple sclerosis. Annu. Rev. Immunol. 2014, 32, 257-281.
16. Lassmann, H., Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease. J. Neural Transm. 2011, 118, 747-752.
17. Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M. et al., Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 2011, 365, 2188-2197.
18. Brandão, C. O., Ruocco, H. H., Farias, A. S., Oliveira, C. et al., Intrathecal immunoglobulin G synthesis and brain injury by quantitative MRI in multiple sclerosis. Neuroimmunomodulation 2006, 13, 89-95.
19. Friese, M. A., Schattling, B., Fugger, L., Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat. Rev. Neurol. 2014, 10, 225-238.
20. Filippi, M., Rocca, M. A., Multiple sclerosis: new measures to monitor the disease. Lancet Neurol. 2013, 12, 12-13.
21. Narayana, P. A., Doyle, T. J., Lai, D., Wolinsky, J. S., Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann. Neurol. 1998, 43, 56-71.
22. Fu, L., Matthews, P. M., DeStefano, N., Worsley, K. J. et al., Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998, 121, 103-113.
23. Lassmann, H., Multiple sclerosis: is there neurodegeneration independent from inflammation? J. Neurol. Sci. 2007, 259, 3-6.
24. Kutzelnigg, A., Lassmann, H., Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb. Clin. Neurol. 2014, 122, 15-58.
25. Milo, R., Miller, A., Revised diagnostic criteria of multiple sclerosis. Autoimmun. Rev. 2014, 13, 518-524.
26. Link, H., Huang, Y.-M., Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J. Neuimmunol. 2006, 180, 17-28.
27. Chu, A. B., Sever, J. L., Madden, D. L., Iivanainen, M. et al., Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases. Ann. Neurol. 1983, 13, 434-439.
28. Hampel, H., Kötter, H. U., Padberg, F., Körschenhausen, D. A., Möller, H. J., Oligoclonal bands and blood-cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. Alzheimer Dis. Assoc. Disord. 1999, 13, 9-19.
29. Wengert, O., Rothenfusser-Korber, E., Vollrath, B., Bohner, G. et al., Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J. Neurol. Sci. 2013, 335, 124-130.
30. Miller, D. H., Buchanan, N., Barker, G., Morrissey, S. P. et al., Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus. J. Neurol. 1992, 239, 460-464.
31. Harris, V. K., Sadiq, S. A., Biomarkers of therapeutic response in multiple sclerosis: current status. Mol. Diagn. Ther. 2014, 1-13.
32. Ben Nun, A., Kaushansky, N., Kawakami, N., Krishnamoorthy, G. et al., From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development. J. Autoimmun. 2014, 54, 33-50.
33. Robinson, A. P., Harp, C. T., Noronha, A., Miller, S. D., The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb. Clin. Neurol. 2014, 122, 173-189.
34. Rivers, T. M., Sprunt, D. H., Berry, G. P., Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 1933, 58, 39-53.
35. Baxter, A. G., The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7, 904-912.
36. Kaltsonoudis, E., Voulgari, P. V., Konitsiotis, S., Drosos, A. A., Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun. Rev. 2014, 13, 54-58.
37. Farias, A. S., Martins-de-Souza, D., Guimarães, L., Pradella, F. et al., Proteome analysis of spinal cord during the clinical course of monophasic experimental autoimmune encephalomyelitis. Proteomics 2012, 12, 2656-2662.
38. Farias, A. S., Pradella, F., Schmitt, A., Santos, L. M. B., Martins-de-Souza, D., Ten years of proteomics in multiple sclerosis. Proteomics 2014, 14, 467-480.
39. Filiou, M. D., Turck, C. W., General overview: biomarkers in neuroscience research. Int. Rev. Neurobiol. 2011, 101, 1-17.
40. Martins-de-Souza, D., Alsaif, M., Ernst, A., Harris, L. W. et al., The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia. BMC Res. Notes 2012, 5(146), 1-7.
41. Wallin, M. T., Oh, U., Nyalwidhe, J., Semmes, J. et al., Serum proteomic analysis of a pre-symptomatic multiple sclerosis cohort. Eur. J. Neurol. 2015, 22, 591-599.